Adding the OncoScan SCNA analysis to the cfDNA profiling did not increase the number of positive findings in the prospective cohorts and only included one more patient (P35, prostate cancer with AR amplification) in the retrospective cohort. This evidence concerns the gene AR and prostate carcinoma.